公司概覽
業務類別 Biotechnology
業務概覽 BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
公司地址 770 Lindaro Street, San Rafael, CA, USA, 94901
電話號碼 +1 415 506-6700
傳真號碼 +1 415 382-7889
公司網頁 https://www.biomarin.com
員工數量 3221
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Cristin Hubbard Executive Vice President and Chief Commercial Officer 美元 662.31K 21/04/2026
Ms. Rashmi Virendra Ramchandani Vice President and Chief Accounting Officer -- 21/04/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 美元 1.13M 21/04/2026
Mr. G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary -- 21/04/2026
Mr. Brian R. Mueller Executive Vice President and Chief Financial Officer 美元 721.15K 21/04/2026
Dr. Charles Greg Guyer, PhD Chief Technical Officer and Executive Vice President 美元 697.12K 21/04/2026
Dr. Gregory R. Friberg, M.D. Executive Vice President and Chief Research and Development Officer 美元 705.65K 21/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Richard A. Meier Chairman of the Board 21/04/2026
Dr. Willard H. Dere, M.D. Independent Director 21/04/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 21/04/2026
Mr. Robert J. Hombach Independent Director 21/04/2026
Dr. Maykin Ho, PhD Independent Director 21/04/2026
Mr. Ian T. Clark Independent Director 21/04/2026
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director 21/04/2026
Mr. Timothy P. Walbert Independent Director 21/04/2026
Ms. Barbara W. Bodem Independent Director 21/04/2026
Mr. Mark Joseph Enyedy Independent Director 21/04/2026
Dr. Athena Countouriotis, M.D. Independent Director 21/04/2026
 
所屬ETF (更新日期: 02/05/2026 04:43)
代號 名稱 佔比% 持有日期
SCHXSchwab US Large-Cap ETF™0.10%29/04/2026
MDYGState Street® SPDR® S&P 400™ Md Cp GrETF0.09%29/04/2026
VTVanguard Total World Stock ETF0.08%31/03/2026
JHMMJHancock Multifactor Mid Cap ETF0.08%29/04/2026
DFATDimensional US Targeted Value ETF0.08%29/04/2026
FXHFirst Trust Health Care AlphaDEX® ETF0.07%29/04/2026
IWBiShares Russell 1000 ETF0.07%29/04/2026
MDYVState Street® SPDR® S&P 400™ Md CpValETF0.07%29/04/2026
VONVVanguard Russell 1000 Value ETF0.06%31/03/2026
SCHBSchwab US Broad Market ETF™0.06%29/04/2026
FELVFidelity Enhanced Large Cap Value ETF0.06%29/04/2026
PBEInvesco Biotechnology & Genome ETF0.06%29/04/2026
IVOGVanguard S&P Mid-Cap 400 Growth ETF0.05%31/03/2026
JMEEJPMorgan Small & Mid Cap Enh Eq ETF0.05%29/04/2026
IYHiShares US Healthcare ETF0.05%29/04/2026
SCHVSchwab US Large-Cap Value ETF™0.05%29/04/2026
IUSGiShares Core S&P US Growth ETF0.05%29/04/2026
BBHVanEck Biotech ETF0.05%29/04/2026
FELCFidelity Enhanced Large Cap Core ETF0.05%29/04/2026
FHLCFidelity MSCI Health Care ETF0.04%29/04/2026
  1   2    3    4    5    6    7    8    9    10    11    12    13  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.